GlaxoSmithKline Offer To Acquire HGS Represents Full, Fair Value

Date : 05/17/2012 @ 1:54PM
Source : Dow Jones News
Stock : Human Genome Sciences, Inc. (MM) (HGSI)
Quote : 14.24  0.0 (0.00%) @ 2:05AM

GlaxoSmithKline Offer To Acquire HGS Represents Full, Fair Value

GlaxoSmithKline (LSE:GSK)
Historical Stock Chart

5 Years : From Apr 2012 to Apr 2017

Click Here for more GlaxoSmithKline Charts.

GlaxoSmithKline PLC (GSK.LN), a British pharmaceutical company, said Thursday it believes its tender offer for Human Genome Sciences(HGSI) represents full and fair value and is in the best interests of both companies' shareholders, adding that it will continue to proceed with its tender offer.

MAIN FACTS:

-The offer represents a premium of 81 percent to HGS's closing share price of $7.17 on April 18.

-Tender offer to acquire all of Human Genome Sciences outstanding shares for $13.00 per share in cash.

-The offer is not conditioned on due diligence or financing.

-The tender offer will close on June 7.

-GSK's offer incorporates the value of Benlysta, darapladib, albiglutide and HGS's pipeline and financial assets.

-It also reflects expected cost synergies of at least $200 million.

-Shares at 1723 GMT down 1%, at 1409 pence, valuing the company at GBP71 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com




Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.